Alzheimer's disease: from bench side to bed side

Alzheimer's disease: from bench side to bed side

Drug systematic administration to brain is challenged by blood–brain barrier (BBB). Only small lipophilic drugs cross BBB. Nearly 100% of biologics cannot cross BBB. Biologics composed 33% of FDA-approved drugs in 2019. Nanoparticles were used to cross BBB after suitable surface modification with mo...

Full description

Saved in:
Bibliographic Details
Main Authors: Mohamed, Wael Mohamed Yousef, Yoon, Chee Kok, Doolaanea, Abd Almonem
Format: Conference or Workshop Item
Language:English
English
English
English
English
Published: 2020
Subjects:
RM Therapeutics. Pharmacology
RS Pharmacy and materia medica
Online Access:http://irep.iium.edu.my/88240/2/BNC%202020%20Hi5%202020%20Dr%20Abd%20Almonem.pdf
http://irep.iium.edu.my/88240/14/Hi5%202020_Tentative_Final_29%20NOV%202020.pdf
http://irep.iium.edu.my/88240/15/E%20PROGRAM%20BOOK%20BNC%20Hi5%20Retreat%202020.pdf
http://irep.iium.edu.my/88240/17/Translational%20Forum%20Invitation%20Letter_%20Dr%20Wael%20et%20al.pdf
http://irep.iium.edu.my/88240/16/01%20Cert_Hi5_Attendance.pdf
http://irep.iium.edu.my/88240/
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Universiti Islam Antarabangsa Malaysia
Language: English
English
English
English
English
Description
Summary:Drug systematic administration to brain is challenged by blood–brain barrier (BBB). Only small lipophilic drugs cross BBB. Nearly 100% of biologics cannot cross BBB. Biologics composed 33% of FDA-approved drugs in 2019. Nanoparticles were used to cross BBB after suitable surface modification with molecules to recognize receptors on BBB.

Similar Items